Determining of optimal routine exchange frequency to minimize costs associated with long-term percutaneous nephrostomy (PCN) management for patients with malignant urinary obstruction

J. McDevitt1, S. Acosta-Torres1, N. Zhang1, T. Hu1, A. Odu1, J. Wang1, X. Yin1, D. Lamus1, D. Miller1, A. Pillai1; 1UT Southwestern Medical Center, Dallas, TX

Purpose: To determine the optimal time for routine exchange of indwelling percutaneous nephrostomies (PCNs) in patients with malignant urinary obstruction and to quantify the effect of patient adherence to scheduled exchanges.

Materials: We retrospectively reviewed patients with malignant urinary obstruction who underwent placement of PCN with at least one subsequent exchange from 2011-2013. Exchanges were classified as routine or due to one of three complication types: mechanical (tube dislodgement), obstruction, or infection. Charges for each complication type were defined as the median value from representative cases. The distribution of exchange types under different routine exchange frequencies was estimated with an Accelerated Failure Time Model and average yearly PCN-related hospital charges were estimated with a Markov Chain Monte Carlo model.

Results: 54 patients with 107 exchange encounters met criteria for inclusion. Median hospital charges were $3.4k for routine exchanges, $40.6k for infection, and $32.0k for obstruction. A model predicted that with a 90-day routine exchange and 50% adherence, 23% of exchanges would be routine and 31% due to infection, which were projected to improve to 44% and 18%, respectively, with a 60-day routine exchange and 75% adherence. Estimated yearly PCN-related hospital charges were $253k without mandated routine exchanges, and were lowest with 60-day routine exchange and 75% adherence. Exchange at 30 days produced the second-most savings ($21.0k ± $1.1k with 75% adherence), with exchange at 60 days producing the second-most savings ($23.4k ± $1.1k with 75% adherence), with exchange at 30 days producing the second-most savings ($21.0k ± $1.1k with 75% adherence). Projected savings increased with patient adherence, as projected savings with 60-day exchange were reduced to $7.8k ± $0.7k if adherence fell to 25%.

Conclusions: Scheduled routine PCN exchanges every 1-2 months is the least costly strategy for patients with malignant ureteral obstruction.

Annual reduction in charges per patient at various routine exchange intervals with 75% adherence.

<table>
<thead>
<tr>
<th>Exchange Interval (days)</th>
<th>Savings ($ thousands)</th>
<th>95% Confidence Interval ($ thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>21.0</td>
<td>(19.2, 22.8)</td>
</tr>
<tr>
<td>60</td>
<td>23.4</td>
<td>(22.3, 24.5)</td>
</tr>
<tr>
<td>90</td>
<td>17.3</td>
<td>(15.6, 18.3)</td>
</tr>
<tr>
<td>120</td>
<td>7.8</td>
<td>(7.4, 8.3)</td>
</tr>
</tbody>
</table>

MRI fused cone-beam CT-guided biopsy of the prostate as a safe and novel method of prostate biopsy

R. Regan1, B. Mussari1, J. Izard, A. Menard1; 1Kingston General Hospital, Kingston, Ontario

Purpose: 3D fluoroscopy guidance using cone-beam CT (CBCT) can be fused to MRI images, allowing direct coaxial needle
placement into an MRI target using the real-time fluoroscopy. Our objective is to describe our initial experience using MRI fused CBCT guidance for prostate biopsy. To date, there are no reports on the use of this biopsy guidance system in the prostate. We hypothesize this technique will have an adequate safety profile while accurately detecting prostate cancer.

**Materials:** Patients were selected for this study if they had undergone a previously negative TRUSP biopsy or previous TRUSP biopsy showing low volume Gleason 6 pathology (low risk disease), all of which are incongruent with the assigned PI-RADS score (≥ 3) of an MRI lesion and/or the PSA level. All of our prostate biopsies were completed using MRI fused CBCT as a navigation system using a transgluteal approach. Dedicated software (XperGuide, Philips Imaging) was used to plan the approach and confirm the location of the coaxial needle prior to biopsy. The immediate and 30-day complication rate and biopsy results were recorded.

**Results:** In total, 20 patients underwent CBCT-guided biopsy. The procedure was well tolerated with no immediate or 30 day complications. Thirteen of the 20 patients had previously received negative results from their TRUSP biopsy. Out of this cohort, CBCT-guided biopsy produced 7 positive biopsies. In 4 patients, the Gleason score was ≥ 7. In the remaining 3 biopsies, a low volume Gleason score of 6 was established, also upgrading the disease. The remaining 7 patients had previous positive TRUSP biopsies that demonstrated low volume Gleason 6 disease. The CBCT-guided biopsy upgraded 1 patient’s pathology to Gleason 7 disease and confirmed a second patients’ Gleason 6 results. Four of the 11 PI-RADS 3 lesions were upgraded to Gleason ≥ 7. The 2 PI-RADS 3 lesions did not demonstrate disease.

**Conclusions:** MRI-fused CBCT guidance is a technically feasible navigation system with no complications in our limited 20 biopsy experience. It has the potential to upstage disease in patients with high PI-RADS lesions on MRI.

**3:45 PM Abstract No. 327**

A prospective randomized study of a covered metallic ureteral stent versus double J Stent for malignant ureteral obstruction: PRODUCE study (NCT01823575)

J. Shin1, J. Kim2, J. Kim3, H. Ko4, D. Gwon6; 1Asan Medical Center, University of Ulsan, Seoul, Republic of Korea; 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 3Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 4Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 5Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

**Purpose:** To assess the safety and efficacy of a covered metallic ureteral stent versus double J stent for the treatment of malignant ureteral obstruction.

**Materials:** Eighteen patients were randomized to fully silicone-covered metallic ureteral stent (group A) or double J stent (group B). The stent is 7-mm and 8-Fr in groups A and B, respectively. The followings were compared between the two groups; technical success (successful stent placement into desired locations), stent malfunction, stent patency (no obstruction and no additional intervention), complications, and survival.

**Results:** Technical success was 100% in all nine and 12 renal units in groups A and B, respectively. During the mean follow-up period of 239.0 days (range, 63 — 572 d), stent malfunction was observed in 44.4% (4/9) and 66.7% (8/12) in groups A and B, respectively. The median patency rates for groups A and B were 239.0 days ± 23.2 (95% confidence intervals [CIs]: 193.6 — 284.4) and 80 days ± 23.2 (95% CIs: 34.6 — 125.4), respectively. Metallic ureteral stents yielded higher patency rates at 90- and 180 days (89% vs. 35% and 49% vs. 21%), despite no significant differences in overall patency rates between two groups (P = .079). Complications included migration of two metallic stents in one patient in group A, which were removed by retrograde manner, followed by double J stent insertion. The two groups did not differ significantly in overall survival rates (P = .508).

**Conclusions:** Metallic ureteral stents can be effective for malignant ureteral obstruction. A multicenter study with a greater patient cohort is warranted to further assess the outcomes after the application of metallic ureteral stents for malignant ureteral obstruction.

**3:54 PM Abstract No. 328**

Outcomes after nephrostomy tube placement in pregnant patients with ureteral obstruction

D. Collins1, A. Malhotra1, A. Herr1, C. Stark1, L. Keating1, M. Englander1, K. Mandato1, G. Siskin1; 1Albany Medical Center, Albany, NY

**Purpose:** To review the outcomes after nephrostomy tube placement in pregnant patients with ureteral obstruction.

**Materials:** A retrospective analysis of pregnant female patients undergoing nephrostomy tube placement during a 5-year period (2010-2015) was performed and outcomes from tube placement through delivery were assessed.

**Results:** Thirty patients (mean age = 26.6 years; range: 18-37) underwent nephrostomy tube placement during pregnancy; 25/30 were followed to delivery (4/30 continued their care closer to home; 1/30 is still pregnant). The mean gestational age at the time of tube placement was 25.4 weeks (range: 5-32 weeks). The etiology of obstruction included renal calculi (n = 10), pyelonephritis (n = 7), congenital or surgical abnormalities (n = 2), ovarian hyperstimulation syndrome (n = 1), and unknown (n = 10). 70% (n = 21) of patients required 2 or more tube changes during pregnancy; the mean number of tube changes during pregnancy was 4.6. Unscheduled tube changes due to decreased urine output were performed in 11 patients at a mean of 21.5 days after tube placement. This prompted 10 patients to undergo tube changes at 1-2 week intervals until delivery. 36.7% (n = 11) of patients required general or MAC anesthesia for the tube placement or change. The mean gestational age at delivery was 37.7 weeks (range 29-40 weeks) with 3 premature births recorded (12%). Caesarean section was performed in 14 of 25 (56%) patients.

**Conclusions:** While symptomatic ureteral obstruction during pregnancy is uncommon, its management in this patient population can be challenging. This retrospective review demonstrates that the changes in urine chemistry during pregnancy can lead to short-term nephrostomy tube obstruction, requiring